Key Details
Annual Revenue
$4.86 MAnnual ROE
-113.18%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 08, 2021Recent annual earnings:
Mar 01, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 18, 2023Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with ACGN included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Aceragen doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
MoonFox Analysis | "ACGN Merch Economy" Surge and the Breakthrough of the "Dimension Wall" in ACGN Consumption
ACGN
prnewswire.com26 December 2024
About us: Aurora Mobile (NASDAQ: JG) established in 2011, is a leading customer engagement and marketing technology service provider in China. Its business includes notification services, marketing growth, development tools, and data products.
FAQ
- What is the primary business of Aceragen?
- What is the ticker symbol for Aceragen?
- Does Aceragen pay dividends?
- What sector is Aceragen in?
- What industry is Aceragen in?
- What country is Aceragen based in?
- When did Aceragen go public?
- Is Aceragen in the S&P 500?
- Is Aceragen in the NASDAQ 100?
- Is Aceragen in the Dow Jones?
- When was Aceragen's last earnings report?
- When does Aceragen report earnings?
- Should I buy Aceragen stock now?
What is the primary business of Aceragen?
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
What is the ticker symbol for Aceragen?
The ticker symbol for Aceragen is NASDAQ:ACGN
Does Aceragen pay dividends?
No, Aceragen does not pay dividends
What sector is Aceragen in?
Aceragen is in the Healthcare sector
What industry is Aceragen in?
Aceragen is in the Biotechnology industry
What country is Aceragen based in?
Aceragen is headquartered in United States
When did Aceragen go public?
Aceragen's initial public offering (IPO) was on 25 January 1996
Is Aceragen in the S&P 500?
No, Aceragen is not included in the S&P 500 index
Is Aceragen in the NASDAQ 100?
No, Aceragen is not included in the NASDAQ 100 index
Is Aceragen in the Dow Jones?
No, Aceragen is not included in the Dow Jones index
When was Aceragen's last earnings report?
Aceragen's most recent earnings report was on 8 November 2021
When does Aceragen report earnings?
The date for Aceragen's next earnings report has not been announced yet
Should I buy Aceragen stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions